1 |
A.L. Dallob, N.S. Sadick, W. Unger, S. Lipert, L.A. Geissler, S.L. Gregoire, H.H. Nguyen, E.C. Moore, W.K. Tanaka, The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness, J. Clin. Endocrinol. Metab., 79(3), 703-706 (1994)
DOI
|
2 |
M.L. Constanzer, B.K. Matuszewski, W.F. Bayne, High-performance liquid chromatographic method for the determination of finasteride in human plasma at therapeutic doses, J. Chromatogr., 566(1), 127-134 (1991)
DOI
ScienceOn
|
3 |
Statistical Solutions Ltd., Equiv 2.0, U.K. (2001)
|
4 |
G.H. Rasmusson, G.F. Reynolds, N.G Steinberg, E. Walton, G.F. Patel, T. Liang, M.A. Cascieri, A.H. Cheung, J.R. Brooks, C. Berman, Azasteroids: structure-activity relationships for inhibition of 5 alpha-reductase and of androgen receptor binding, J. Med. Chem., 29(11), 2298-2315 (1986)
DOI
|
5 |
M. Ohtawa, H. Morikawa, J. Shimazaki, Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 -androst-1-ene-17 -carboxamide, a new type of specific competitive inhibitor of testosterone 5a-reductase, in volunteers, Eur. J. Drug Metab. Pharmacokinet., 16(1), 15-21 (1991)
DOI
|
6 |
식품의약품안전청 고시 제 2002-60호, 생물학적동등성시험기준 (2002. 11. 22)
|
7 |
식품의약품안전청 고시 제 1999-67호, 의약품임상시험관리기준 (2000. 1. 4)
|
8 |
P. Ptacek, J. Macek, J. Klima, Determination of finasteride in human plasma by liquid-liquid extraction and high-performance liquid chromatography, J. Chromatogr. B, 738, 305-310(2000)
DOI
ScienceOn
|